PharmaMar SA: Revenue generating with marine-derived and novel MoA oncology products. 2018 total revenues of €162M. Yondelis (soft tissue sarcoma and ovarian cancer) commercialized with direct sales-force in EU and partnership in US with Janssen. Zepsyre (lurbinectedin), optimized analog of Yondelis, reported positive Ph 2 results - company will file its NDA under accelerated approval for lurbinectedin monotherapy for the treatment of relapsed SCLC during Q4, 2019, with potential approval and US launch in 2020.
Sector/industry:
Healthcare/Biotechnology
Characteristics:
Based in...
Europe
Clinical Stage
Marketed
Disease Space
Oncology
Finance
Profitable
Industry
Biotechnology
Listing
Public
Therapeutic Modalities
Platform Technology, Small Molecule
Website:
Address:
Plaza del Descubridor Diego de Ordás 3
5th Floor
Madrid, 28003
Spain

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Upcoming Company Event Participation

Solebury Trout Management Access: SF 2020

San Francisco, CA, United States, January 13 – January 16, 2020

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2019 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.